Scholarlink

<p>Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), and mescaline induce lasting changes in neuroplasticity and behavior that extend far beyond their acute pharmacological effects. Emerging evidence highlights that these enduring therapeutic benefits in neuropsychiatric conditions may be significantly mediated through complex epigenetic reprogramming mechanisms, although direct causal evidence remains limited. This review synthesizes current knowledge on how classical psychedelics and the rapid-acting antidepressant ketamine (an NMDA receptor antagonist) influence epigenetic regulation at multiple molecular levels, encompassing DNA methylation and hydroxymethylation, histone post-translational modifications (acetylation, methylation, phosphorylation), nucleosome positioning and higher-order chromatin restructuring, non-coding RNA (ncRNA) dynamics, and RNA epitranscriptomic modifications. Moreover, psychedelics appear to alter metabolic and mitochondrial pathways, thereby modulating the availability and nuclear transport of key epigenetic cofactors, such as acetyl-CoA, S-adenosylmethionine (SAM), and α-ketoglutarate. By integrating these pathways, we propose a unified model wherein psychedelic-induced signaling cascades may intersect with metabolic and epigenetic networks, potentially contributing to persistent transcriptional alterations and enhanced synaptic connectivity. Understanding these intricate mechanisms provides crucial insights into how transient exposure to psychedelics translates into sustained therapeutic outcomes, informing the development of novel neuroepigenetic interventions in molecular psychiatry.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation

  • 期刊论文

  • 发表日期：

    2026年7月10日

查看全文
  • Cong Lin,
  • Xiaohui Wang

摘要

Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), and mescaline induce lasting changes in neuroplasticity and behavior that extend far beyond their acute pharmacological effects. Emerging evidence highlights that these enduring therapeutic benefits in neuropsychiatric conditions may be significantly mediated through complex epigenetic reprogramming mechanisms, although direct causal evidence remains limited. This review synthesizes current knowledge on how classical psychedelics and the rapid-acting antidepressant ketamine (an NMDA receptor antagonist) influence epigenetic regulation at multiple molecular levels, encompassing DNA methylation and hydroxymethylation, histone post-translational modifications (acetylation, methylation, phosphorylation), nucleosome positioning and higher-order chromatin restructuring, non-coding RNA (ncRNA) dynamics, and RNA epitranscriptomic modifications. Moreover, psychedelics appear to alter metabolic and mitochondrial pathways, thereby modulating the availability and nuclear transport of key epigenetic cofactors, such as acetyl-CoA, S-adenosylmethionine (SAM), and α-ketoglutarate. By integrating these pathways, we propose a unified model wherein psychedelic-induced signaling cascades may intersect with metabolic and epigenetic networks, potentially contributing to persistent transcriptional alterations and enhanced synaptic connectivity. Understanding these intricate mechanisms provides crucial insights into how transient exposure to psychedelics translates into sustained therapeutic outcomes, informing the development of novel neuroepigenetic interventions in molecular psychiatry.